IV ketamine for depression

Off-label IV ketamine

Ketamine’s FDA-approved purpose is anesthesia. IV ketamine for depression is an off-label clinical decision, distinct from FDA-approved nasal Spravato. The psychiatrist should explain the intended condition, evidence, uncertainty, alternatives and how benefit is reviewed. An infusion requires a suitable monitored setting and a program-specific protocol. A rapid or lasting response is not guaranteed. Confirm whether the selected clinic currently offers IV treatment. Compounded or home products should not be assumed equivalent to a monitored infusion or nasal Spravato.

IV ketamine for depression

IV ketamine for depression uses ketamine by an intravenous infusion outside its FDA-approved anesthetic indication. This is an off-label treatment decision. It is different from Spravato, the nasal esketamine product with specific adult depression indications and a REMS. The two treatments differ in formulation, dose planning, monitoring requirements and insurance pathways. Ask whether IV treatment is currently offered and which location, clinician and monitored setting would provide it.

How IV ketamine for depression works

Ketamine affects NMDA receptors and other brain signalling systems. Its antidepressant mechanism is not fully understood. Research and guidelines support discussion of ketamine as an advanced option in selected difficult-to-treat depression cases, but a rapid response is not guaranteed. A strong subjective experience during an infusion does not establish lasting benefit.

Eligibility: IV ketamine for depression

A psychiatrist reviews the depressive illness, adequate previous treatment trials, current risk, other diagnoses and the alternatives. The assessment also reviews cardiovascular health, substance-use risks, pregnancy, liver history and medicines that may affect sedation or blood pressure. The clinician should explain why off-label IV ketamine is being considered and how outcomes and harms will be assessed. A suicidal crisis needs urgent safety care independently of a planned infusion.

What to expect: IV ketamine for depression

Discuss evidence and alternatives

Ask about the intended condition, expected benefit, uncertainty and alternatives such as established medicines, psychotherapy or a referral for brain stimulation. Off-label prescribing is a clinical decision. It does not mean FDA has approved a depression dose or schedule.

Confirm an appropriate monitored setting

Ask who will administer and monitor the infusion, how breathing, blood pressure and alertness will be assessed, and how an emergency will be handled. Do not transfer onsite infusion information to an unsupervised home or compounded nasal regimen.

Agree on a review and continuation plan

Before starting, agree on symptom and function measures, when benefit will be reviewed and what happens if there is little improvement or adverse effects. Session numbers and maintenance intervals must come from the treating program. They cannot be inferred from the Spravato label.

Preparing for your appointment

Bring the treatment history and a full medicine and substance-use list. Obtain the program’s written eating, drinking and medication instructions. Do not substitute the Spravato food rules for an infusion protocol. Arrange transport home and time away from driving and hazardous work. Ask about support after discharge, responsibilities later that day and whom to call about a concerning symptom.

Risks and when to seek help

Ketamine can cause sedation, dissociation, higher blood pressure and breathing problems. Misuse and dependence risks, urinary symptoms and other adverse effects require discussion, especially with repeated exposure. MedlinePlus advises no driving or machinery for at least 24 hours after ketamine injection. Follow any longer restriction from the treating clinician. Call 911 for breathing difficulty, fainting or a serious allergic reaction. Report urinary pain, troubling confusion or worsening mood to the treating clinician.

Follow-up and treatment review

Track changes in mood, daily function, adverse effects and the duration of any improvement. If symptoms return between sessions, contact the treating psychiatrist rather than arranging an unsupervised dose increase. There is no Spravato-label maintenance schedule that can simply be applied to IV ketamine. A switch between formulations requires a new clinical and practical review.

Appointments, costs and coverage

Ask for a written estimate for assessment, infusion, monitoring and follow-up. Coverage of a psychiatry visit does not prove coverage of off-label ketamine. Confirm which services are submitted to insurance and which are self-pay before treatment. Confirm the actual infusion service, responsible clinician, supply and estimate before making treatment arrangements.

Questions about your care

Is IV ketamine FDA-approved for depression?

No. Its psychiatric use is off-label. FDA-approved nasal Spravato has separate indications and safeguards; it does not make IV ketamine an approved depression treatment.

Can I use Spravato’s schedule for infusions?

No. The infusion plan is a separate clinical protocol. Ask how many sessions are proposed, how response is measured and how continuation will be decided.

How do I plan driving and work afterwards?

Arrange a ride home and follow the clinician’s instructions. Ketamine-injection patient information advises avoiding driving and machinery for at least 24 hours; your program may impose a longer restriction.

Why might insurance cover Spravato but not infusions?

The formulation and regulatory status differ, and insurers apply different benefits and authorization rules. Obtain a plan-specific determination and written estimate rather than relying on another patient’s claim history.

What if symptoms return during maintenance?

Contact the treating psychiatrist for reassessment of symptoms, safety and the treatment plan. Do not switch routes, increase frequency or add compounded ketamine yourself.